Literature DB >> 12693391

Balancing safety, effectiveness, and public desire: the FDA and cancer.

Rena Conti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12693391      PMCID： PMC4591854     

Source DB:  PubMed          Journal:  Issue Brief (Commonw Fund)        ISSN： 1558-6847


× No keyword cloud information.
  9 in total

Review 1.  Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

Authors:  K A Gelmon; E A Eisenhauer; A L Harris; M J Ratain; P Workman
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

Review 2.  Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.

Authors:  E A Sausville; E Feigal
Journal:  Ann Oncol       Date:  1999-11       Impact factor: 32.976

Review 3.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 4.  The promise and peril of surrogate end points in cancer research.

Authors:  Arthur Schatzkin; Mitchell Gail
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

5.  The case for a new national program for the development of cancer therapeutics.

Authors:  P S Schein
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

6.  Testing of new agents in childhood cancer preclinical models: meeting summary.

Authors:  Peter J Houghton; Peter C Adamson; Susan Blaney; Howard A Fine; Richard Gorlick; Michelle Haber; Lee Helman; Steve Hirschfeld; Melinda G Hollingshead; Mark A Israel; Richard B Lock; John M Maris; Glenn Merlino; Wendy Patterson; C Patrick Reynolds; Kevin Shannon; Alice Yu; John Yu; Malcolm A Smith
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

Review 7.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 9.  Molecules for the millennium: how will they look? New drug discovery year 2000.

Authors:  E A Sausville; J I Johnson
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.